BioLineRx is trading at 2.98 as of the 3rd of March 2025. This is a No Change since the beginning of the trading day. The stock's lowest day price was 2.98. BioLineRx has about a 41 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. BioLineRx has reported 40 for 1 split on 30th of January 2025. The performance scores are derived for the period starting the 1st of February 2025 and ending today, the 3rd of March 2025. Click here to learn more.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd. was founded in 2003 and is headquartered in Hevel Modiin, Israel. BIOLIN RX operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. The company has 61.52 M outstanding shares. More on BioLineRx
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BioLineRx's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BioLineRx or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
BioLineRx (YP2A) is traded on Frankfurt Exchange in Germany and employs 38 people. The company currently falls under 'Micro-Cap' category with a current market capitalization of 35.19 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioLineRx's market, we take the total number of its shares issued and multiply it by BioLineRx's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BioLineRx operates under Healthcare sector and is part of Biotechnology industry. The entity has 61.52 M outstanding shares.
BioLineRx has accumulated about 58.08 M in cash with (23.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.36.
Check BioLineRx Probability Of BankruptcyOwnership AllocationBioLineRx holds a total of 61.52 Million outstanding shares. Almost 89.07 percent of BioLineRx outstanding shares are held by general public with 10.93 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Although BioLineRx's alpha and beta are two of the key measurements used to evaluate BioLineRx's performance over the market, the standard measures of volatility play an important role as well.
Our tools can tell you how much better you can do entering a position in BioLineRx without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run AI Portfolio Architect Now
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Elected by the shareholders, the BioLineRx's board of directors comprises two types of representatives: BioLineRx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioLineRx. The board's role is to monitor BioLineRx's management team and ensure that shareholders' interests are well served. BioLineRx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioLineRx's outside directors are responsible for providing unbiased perspectives on the board's policies.
Additional Information and Resources on Investing in BioLineRx Stock
When determining whether BioLineRx offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioLineRx's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biolinerx Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biolinerx Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in BioLineRx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioLineRx Stock please use our How to Invest in BioLineRx guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Please note, there is a significant difference between BioLineRx's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioLineRx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioLineRx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.